|
ETF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.51829999994746E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.59619999995364E-06 |
| Normal-vs-Stage2 |
1.266020E-02 |
| Normal-vs-Stage3 |
1.6929999999693E-06 |
| Normal-vs-Stage4 |
4.90210000037017E-07 |
| Stage1-vs-Stage2 |
4.504400E-02 |
| Stage1-vs-Stage3 |
6.557000E-01 |
| Stage1-vs-Stage4 |
2.692200E-01 |
| Stage2-vs-Stage3 |
4.112300E-02 |
| Stage2-vs-Stage4 |
1.878340E-02 |
| Stage3-vs-Stage4 |
4.819200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.42319999996143E-06 |
| Normal-vs-AfricanAmerican |
4.057900E-02 |
| Normal-vs-Asian |
4.77900000017684E-07 |
| Caucasian-vs-AfricanAmerican |
1.184640E-01 |
| Caucasian-vs-Asian |
2.194600E-01 |
| AfricanAmerican-vs-Asian |
2.878200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.41669999859695E-08 |
| Normal-vs-Female |
3.23010000002899E-06 |
| Male-vs-Female |
2.803200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.0522999999727E-06 |
| Normal-vs-Age(41-60Yrs) |
1.01060000001763E-06 |
| Normal-vs-Age(61-80Yrs) |
1.97535999999499E-05 |
| Normal-vs-Age(81-100Yrs) |
3.833800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.567600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.341200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.286000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.508600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.874200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.558000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.542200E-01 |
| Classical-VS-Follicular |
7.331800E-01 |
| Classical-VS-Other |
3.708200E-02 |
| Classical-VS-Normal |
2.0245999999946E-05 |
| Tall-VS-Follicular |
4.872200E-01 |
| Tall-VS-Other |
1.395000E-01 |
| Tall-VS-Normal |
2.25709999999157E-05 |
| Follicular-VS-Other |
1.108820E-01 |
| Follicular-VS-Normal |
3.5695999999974E-05 |
| Other-VS-Normal |
1.382760E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.63150000001655E-06 |
| Normal-vs-N1 |
3.1445000048258E-08 |
| N0-vs-N1 |
2.383800E-02 |
|
|
